Respiratory Research

Table 2 Adjusted mean FEV₁ AUC_0–24, AUC_0–12 and AUC_12–24 responses at 3 weeks

From: Randomised, double-blind, placebo-controlled crossover study to investigate different dosing regimens of olodaterol delivered via Respimat® in patients with moderate to severe persistent asthma

				Difference from placebo, L
End point	Treatment, μg	n	Mean FEV₁ AUC response, L (SE)	Mean (SE)	95 % CI	p value
FEV₁ AUC_0–24 response	Placebo	200	0.022 (0.020)
	Olodaterol 2.5 BID	99	0.213 (0.024)	0.191 (0.020)	0.152, 0.229	<0.0001
	Olodaterol 5 QD	99	0.173 (0.024)	0.150 (0.020)	0.111, 0.189	<0.0001
	Olodaterol 5 BID	100	0.250 (0.024)	0.228 (0.020)	0.190, 0.266	<0.0001
	Olodaterol 10 QD	101	0.231 (0.024)	0.209 (0.020)	0.170, 0.247	<0.0001
FEV₁ AUC_0–12 response	Placebo	200	0.052 (0.020)
	Olodaterol 2.5 BID	99	0.242 (0.024)	0.190 (0.020)	0.150, 0.229	<0.0001
	Olodaterol 5 QD	99	0.212 (0.024)	0.160 (0.020)	0.121, 0.199	<0.0001
	Olodaterol 5 BID	100	0.266 (0.024)	0.214 (0.020)	0.175, 0.253	<0.0001
	Olodaterol 10 QD	101	0.272 (0.024)	0.219 (0.020)	0.181, 0.258	<0.0001
FEV₁ AUC_12–24 response	Placebo	201	-0.010 (0.020)
	Olodaterol 2.5 BID	99	0.186 (0.025)	0.196 (0.022)	0.153, 0.238	<0.0001
	Olodaterol 5 QD	99	0.135 (0.025)	0.144 (0.022)	0.102, 0.187	<0.0001
	Olodaterol 5 BID	100	0.233 (0.025)	0.242 (0.022)	0.200, 0.285	<0.0001
	Olodaterol 10 QD	101	0.189 (0.025)	0.198 (0.022)	0.156, 0.241	<0.0001

Common study baseline mean (SE): 2.571 (0.054) for all end points
FEV ₁ forced expiratory volume in 1 s, AUC _0–24 area under the curve from 0 to 24 h, AUC _0–12 area under the curve from 0 to 12 h, AUC _12–24 area under the curve from 12 to 24 h, SE standard error, CI confidence interval, BID twice daily, QD once daily

Back to article page

ISSN: 1465-993X

Contact us

General enquiries: journalsubmissions@springernature.com